(Q35809317)

10 August 2017

1 reference

title

Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial (English)

1 reference

amyotrophic lateral sclerosis

10 August 2017

main subject

0 references

Michael Swash

2

0 references

Pamela Shaw

object named as

Pamela Shaw

8

0 references

Vincent Meininger

5

object named as

Vincent Meininger

1 reference

10 August 2017

4

Albert Ludolph

1 reference

10 August 2017

1

P Nigel Leigh

1 reference

10 August 2017

7

Hiroshi Mitsumoto

1 reference

10 August 2017

Leonard H van den Berg

10

object named as

Leonard Van Den Berg

1 reference

10 August 2017

Yasuo Iwasaki

3

1 reference

10 August 2017

Robert G Miller

6

1 reference

10 August 2017

Kunio Tashiro

9

1 reference

10 August 2017

language of work or name

1 reference

1 June 2004

1 reference

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

84-98

1 reference

Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

The epidemiology of ALS in Modena, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

The epidemiology of motor neuron diseases: a review of recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

ALS in Rochester, Minnesota, 1925-1977.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Recent advances in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Progress in the pathogenesis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Pathways to motor neuron degeneration in transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Apoptosis in amyotrophic lateral sclerosis: a review of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Apoptosis and caspases in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Excitotoxic and Excitoprotective Mechanisms: Abundant Targets for the Prevention and Treatment of Neurodegenerative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Programmed cell death in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Targeting programmed cell death in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Prospects for antiapoptotic drug therapy of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Transgenic mouse models and human neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Pentoxifylline reduces biochemical markers of ischemia-reperfusion induced spinal cord injury in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Minocycline delays disease onset and mortality in a transgenic model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Evaluation of memantine for neuroprotection in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Fatigue and depression are associated with poor quality of life in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis: the effect of upper and lower motor neuron lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Motor Unit Number Estimation (MUNE): pro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Clinical neurophysiology of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Disease progression in amyotrophic lateral sclerosis: predictors of survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Interpreting change scores on the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

The ALS Health Profile Study: quality of life of amyotrophic lateral sclerosis patients and carers in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Disease status and use of ventilatory support by ALS patients. BDNF Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820410020187

10.1080/14660820410020187

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference